122
Participants
Start Date
September 21, 2022
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
NRD135SE.1
The double-blind treatment phase is up to 13 weeks.
Placebo
A matching placebo will be taken for up to 13 weeks.
RECRUITING
NYU Langone Manhattan, New York
RECRUITING
Mount Sinai School of Medicine, New York
RECRUITING
Columbia University Medical Center/Neurological Institute, New York
RECRUITING
University of Rochester, Rochester
RECRUITING
University of Pittsburgh, Pittsburgh
RECRUITING
University of Maryland - Baltimore, Baltimore
RECRUITING
Johns Hopkins University School of Medicine, Baltimore
RECRUITING
VCU Department of Neurology, Richmond
RECRUITING
Eastern Virginia Medical School, Norfolk
ACTIVE_NOT_RECRUITING
Low Country Pain Center, Orangeburg
ACTIVE_NOT_RECRUITING
SIMEDHealth LLC, Gainesville
RECRUITING
University of Florida, Gainesville
TERMINATED
South Lake Pain Institute, Clermont
ACTIVE_NOT_RECRUITING
Clinical Inquest Center, Beavercreek
RECRUITING
University of Wisconsin, Madison
RECRUITING
American Indian Clinical Trials Research Network, Rapid City
RECRUITING
Healthcare Research Network (Flossmoor), Flossmoor
RECRUITING
Northwestern Department of Neurology, Chicago
RECRUITING
Healthcare Research Network (Hazelwood), Hazelwood
RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Nerve and Muscle Center of Texas, Houston
ACTIVE_NOT_RECRUITING
Clinicore International, Houston
ACTIVE_NOT_RECRUITING
University of Utah School of Medicine, Salt Lake City
RECRUITING
University of California, San Diego, San Diego
RECRUITING
University of Washington, Seattle
TERMINATED
MGH Department of Anesthesia, Critical Care, and Pain, Boston
New York University
OTHER
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Icahn School of Medicine at Mount Sinai
OTHER
James P. Rathmell, MD
OTHER